Researchers from Washington University in St. Louis found people who took suvorexant, a common treatment for insomnia, for ...

Even as Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla slowly roll out onto the market, experts question the efficacy of ...

This review provides an overview of Alzheimer’s disease (AD), discussing its complex pathophysiology, risk factors, and ...

A new gene editing tool that helps cellular machinery skip parts of genes responsible for diseases has been applied to reduce the formation of amyloid-beta plaque precursors in a mouse model of ...

Bristol Myers Squibb has turned to the source of Leqembi to further its push into Alzheimer’s disease, paying BioArctic $100 ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of acoramidis in the EU based on positive results from the ...

Immune cells in the brain called microglia can partially break down large amyloid plaques characteristic of Alzheimer's disease by latching on to them, forming a sort of external stomach and releasing ...

Preclinical studies have shown AT-02 is able to bind to multiple amyloid types and can induce macrophage mediated amyloid phagocytosis and removal. The Food and Drug Administration has granted Orphan ...

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that it has entered into a global exclusive license agreement with Bristol Myers Squibb (NYSE: BMY) for BioArctic's PyroGlutamate-amyloid ...

Alzheimer’s can be caused by a herpes virus that travels from the gut to the brain, and it may be responsible for up to 45% ...